ANI Pharmaceuticals (ANIP) director reports stock sale and 3,000-share gift

Rhea-AI Filing Summary

ANI Pharmaceuticals director reports stock sale and charitable gift. A company director filed a Form 4 showing the sale of 8,643 shares of ANI Pharmaceuticals Inc. common stock on 11/13/2025 at a weighted average price of $86.88 per share, leaving 61,405 shares beneficially owned immediately after the sale. The same day, the director made a bona fide gift of 3,000 shares of common stock to a donor-advised fund for charitable purposes, with no beneficial ownership or control retained over the donated shares, reducing the director’s holdings to 58,405 shares held directly.

Insider Trade Summary

Net Seller: 11,643 shares

Net Sell 2 txns

Insider Walsh Patrick D

Role Director

Sold 8,643 shs ($751K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,643	$86.88	$751K
Gift	Common Stock	3,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 58,405 shares (Direct)

Footnotes (2)

1. F1. The shares were sold in multiple trades at prices ranging from $86.15 to $87.80. The price reported above reflects the weighted average sales price.
2. F2. This transaction reported on this Form 4 reflects a bona fide gift of Company's common stock to a donor-advised fund ("DAF") for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/17/2025 - 06:01 PM Learn about SEC filing dates

FAQ

What insider transaction was reported for ANI Pharmaceuticals (ANIP)?

A director of ANI Pharmaceuticals Inc. (ANIP) reported on Form 4 that they sold 8,643 shares of common stock and made a separate charitable gift of 3,000 shares on 11/13/2025.

At what price were the ANIP shares sold in the reported transaction?

The 8,643 ANI Pharmaceuticals shares were sold in multiple trades at prices ranging from $86.15 to $87.80, with a weighted average sales price of $86.88 per share.

How many ANI Pharmaceuticals (ANIP) shares does the director own after these transactions?

Following the reported sale and the charitable gift, the director beneficially owns 58,405 shares of ANI Pharmaceuticals common stock, held directly.

What was the nature of the 3,000-share transaction reported for ANIP?

The 3,000-share transaction was a bona fide gift of ANI Pharmaceuticals common stock to a donor-advised fund for charitable purposes, with the reporting person retaining no beneficial ownership or control over those shares.

What is the reporting person’s relationship to ANI Pharmaceuticals (ANIP)?

The reporting person is a director of ANI Pharmaceuticals Inc., as indicated in the Form 4 filing.

Was the ANI Pharmaceuticals Form 4 filed by an individual or a group?

The Form 4 was filed by one reporting person, not by a group, according to the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Patrick D

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		S		8,643	D	$86.88(1)	61,405	D
Common Stock	11/13/2025		G(2)		3,000	D	$0	58,405	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $86.15 to $87.80. The price reported above reflects the weighted average sales price.

2. This transaction reported on this Form 4 reflects a bona fide gift of Company's common stock to a donor-advised fund ("DAF") for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution.

Remarks:

	/s/ Patrick D. Walsh, by attorney-in-fact Meredith W. Cook	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.